TY - JOUR
T1 - Position paper SIC: Trattare per prevenire – la riduzione intensiva del colesterolo LDL nel paziente a rischio cardiovascolare molto alto senza pregresso evento. Dalle linee guida ESC alla pratica clinica
AU - Filardi, Pasquale Perrone
AU - Nardi, Ermanno
AU - Agostoni, Piergiuseppe
AU - Barillà, Francesco
AU - Calabrò, Paolo
AU - Ciccone, Marco Matteo
AU - Curcio, Antonio
AU - Indolfi, Ciro
AU - Muscoli, Saverio
AU - Nodari, Savina
AU - Paolillo, Stefania
AU - Patti, Giuseppe Rocco Salvatore
AU - Porto, Italo
AU - Sinagra, Gianfranco
AU - Gallo, Luca
AU - Fontanarosa, Sara
AU - Vizza, Carmine Dario
AU - Gargiulo, Paola
PY - 2024
Y1 - 2024
N2 - Cardiovascular (CV) diseases account for over 4 million deaths every year in Europe and over 220 000 deaths in Italy, representing the leading cause of morbidity and mortality worldwide. The European Society of Cardiology (ESC) guidelines have visionary included in the at very high CV risk group patients without previous acute ischemic events, such as those with subclinical atherosclerosis, chronic coronary syndrome or peripheral arterial disease, familial hypercholesterolemia, diabetes mellitus with target organ damage or multiple associated risk factors, and those with high calculated CV risk score, recommending to consider them and to achieve the same LDL-cholesterol targets as for secondary prevention patients. The aim of this position paper is to provide an updated overview of ESC guidelines that focuses on these patient categories to raise awareness within the clinical community regarding CV risk reduction in this specific epidemiological context.
AB - Cardiovascular (CV) diseases account for over 4 million deaths every year in Europe and over 220 000 deaths in Italy, representing the leading cause of morbidity and mortality worldwide. The European Society of Cardiology (ESC) guidelines have visionary included in the at very high CV risk group patients without previous acute ischemic events, such as those with subclinical atherosclerosis, chronic coronary syndrome or peripheral arterial disease, familial hypercholesterolemia, diabetes mellitus with target organ damage or multiple associated risk factors, and those with high calculated CV risk score, recommending to consider them and to achieve the same LDL-cholesterol targets as for secondary prevention patients. The aim of this position paper is to provide an updated overview of ESC guidelines that focuses on these patient categories to raise awareness within the clinical community regarding CV risk reduction in this specific epidemiological context.
KW - Cardiovascular prevention
KW - Cardiovascular risk score
KW - Chronic kidney disease
KW - Diabetes mellitus
KW - Familial hypercholesterolemia
KW - LDL-cholesterol
KW - Subclinical atherosclerosis
KW - Cardiovascular prevention
KW - Cardiovascular risk score
KW - Chronic kidney disease
KW - Diabetes mellitus
KW - Familial hypercholesterolemia
KW - LDL-cholesterol
KW - Subclinical atherosclerosis
UR - https://iris.uniupo.it/handle/11579/222551
U2 - 10.1714/4282.42641
DO - 10.1714/4282.42641
M3 - Articolo in rivista
SN - 1972-6481
VL - 25
JO - Giornale Italiano di Cardiologia
JF - Giornale Italiano di Cardiologia
IS - 7
ER -